Moshe Talpaz is an Oncology physician affiliated with University of Michigan. OpenAlex indexes 1,279 publications with 73,545 citations (h-index 124); ClinicalTrials.gov lists 2 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 5% of Medical Oncology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1500 East Medical Center Dr
B1 Floor Cancer Ctr Recp B
Ann Arbor, MI 481095914
Telephone
734-936-9814Registry record last updated 19 Apr 2012.
Clinical trials
- Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation)
Sponsor: Deciphera Pharmaceuticals, LLC
- Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma
Sponsor: University of Michigan Rogel Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Incyte CorporationProgram year20259 payments
- Novartis Pharmaceuticals CorporationProgram year20251 payment
- E.R. Squibb & Sons, L.L.C.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
90.2%Kinase inhibitor35.7%Jakafi100%Part D<11 patientsAntimetabolite27.7%Hydroxyurea100%Part D≥12 patients+ 2 more classes in this area
Other
9.8%Iron Chelator9.8%Deferasirox100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2019–2023 per NIH RePORTER. The latest:
- University of Michigan Quantitative Co-Clinical Imaging Research Resource
University of Michigan at Ann Arbor
FY2023$615,843U24CA237683 - Imaging Disease Heterogeneity and Response to Therapy in Myelofibrosis
University of Michigan at Ann Arbor
FY2023$608,237R01CA238023 - University of Michigan Quantitative Co-Clinical Imaging Research Resource
University of Michigan at Ann Arbor
FY2022$615,843U24CA237683
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
New England Journal of Medicine
2019
Similar KOLs
Other experts from the same institution or the same specialty.
William Herman, MD
University of Michigan
Max Wicha, MD
University of Michigan
Dinesh Khanna, MD
University of Michigan
Eva Feldman, MD
University of Michigan
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”